search button

Metformin and lung cancer risk of patients with type 2 diabetes mellitus: A meta‑analysis

  • Authors:
    • Ning Zhu
    • Yuanyuan Zhang
    • Yi Gong
    • Jian He
    • Xiaodong Chen

  • View Affiliations

  • Published online on: January 9, 2015     https://doi.org/10.3892/br.2015.417
  • Pages: 235-241
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The association between metformin and the lung cancer risk of patients with type 2 diabetes mellitus (T2DM) remains controversial. Therefore, the present meta‑analysis on epidemiological studies was performed to explore this issue. A comprehensive literature search was conducted for all the potential studies addressing metformin use and lung cancer risk by utilizing Pubmed, CBM and ISI Web of Science using the Mesh terms: ‘Metformin,’ or ‘biguanides’ and ‘lung cancer,’ or ‘neoplasms’. The reference lists were also inspected. Eight observational studies, including 17,997 lung cancer patients, were eventually selected, which contained seven case‑control and one cohort study. Compared to other antidiabetic agents, metformin was significantly associated with the 16% reduction of lung cancer risk in type 2 diabetic patients [relative risk (RR)=0.84; 95% confidence interval (95% CI), 0.73‑0.97]. In the sensitivity analysis by separately excluding the study with a high weight or lower quality, the results did not materially change. Subsequently, subgroup analysis was performed on the type of study design, unadjusted or adjusted hazard ratio, quality of enrolled studies, duration of treatment, country and control drugs. The magnitude of lung cancer risk reduction was strengthened when compared to sulfonylureas (RR=0.79; 95% CI, 0.83‑0.9), without significant heterogeneity (Q‑value=2.98, P=0.085). In conclusion, the present analysis supported that the use of metformin significantly decreased the risk of lung cancer among patients with T2DM. However, further studies are required to confirm these findings.
View Figures
View References

Related Articles

Journal Cover

March-2015
Volume 3 Issue 2

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.3
  • Ranked
    (total number of cites)
  • CiteScore: 4.1
  • CiteScore Rank: Q1: #19/80 Pharmacology, Toxicology and Pharmaceutics
  • Source Normalized Impact per Paper (SNIP): 0.7
  • SCImago Journal Rank (SJR): 0.514
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Zhu N, Zhang Y, Gong Y, He J and Chen X: Metformin and lung cancer risk of patients with type 2 diabetes mellitus: A meta‑analysis. Biomed Rep 3: 235-241, 2015.
APA
Zhu, N., Zhang, Y., Gong, Y., He, J., & Chen, X. (2015). Metformin and lung cancer risk of patients with type 2 diabetes mellitus: A meta‑analysis. Biomedical Reports, 3, 235-241. https://doi.org/10.3892/br.2015.417
MLA
Zhu, N., Zhang, Y., Gong, Y., He, J., Chen, X."Metformin and lung cancer risk of patients with type 2 diabetes mellitus: A meta‑analysis". Biomedical Reports 3.2 (2015): 235-241.
Chicago
Zhu, N., Zhang, Y., Gong, Y., He, J., Chen, X."Metformin and lung cancer risk of patients with type 2 diabetes mellitus: A meta‑analysis". Biomedical Reports 3, no. 2 (2015): 235-241. https://doi.org/10.3892/br.2015.417